Posts

Posted on

New Logitech Rally Camera Streamline Kit Keeps All Eyes on Relevant Content

New Logitech Rally Camera Streamline Kit Keeps All Eyes on Relevant Content

Designed for hyflex learning and modern workspaces

LAUSANNE, Switzerland & SAN JOSE, Calif.–(BUSINESS WIRE)–
Logitech (SIX: LOGN) (NASDAQ: LOGI), today introduced Rally Camera Streamline Kit, a comprehensive USB Pan Tilt Zoom (PTZ) video solution designed for hyflex learning environments and modern workspaces. As higher education institutions strive to meet the evolving needs of their audiences, the demand for lecture capture content has never been greater. Whether engaging with content in-person, online or asynchronously, audiences require seamless experiences tailored for their preferences. Built around Logitech’s flagship Rally Camera, the kit enables easy switching between preset camera views, installation and troubleshooting.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250116534411/en/

Introducing the Logitech Rally Camera Streamline Kit, a comprehensive USB Pan Tilt Zoom (PTZ) video solution for hyflex learning (Photo: Business Wire)

Introducing the Logitech Rally Camera Streamline Kit, a comprehensive USB Pan Tilt Zoom (PTZ) video solution for hyflex learning (Photo: Business Wire)

“PTZ cameras with speaker tracking for lecture capture are often overly complex and expensive, adding unnecessary hardware to standard USB AV setups while creating unpredictable and distracting user experiences,” said Michele Hermann, vice president and general manager of Logitech for Education. “The Rally Camera Streamline Kit is an accessible and easy-to-install solution that minimizes setup complexity while enhancing both user experience and content delivery.”

The Rally Camera Streamline Kit enables presenters to stay in the flow and control their narrative, delivering an engaging experience for their audience. Presenters can easily switch preset PTZ views on the camera using intuitive, contextually-placed buttons, simplifying the setup for AV teams while eliminating the need for presenter training required in these spaces.

The solution uses Rally Camera and an Extension Kit, comprised of a camera side base which can be connected and powered up to 100 meters away via category cable to a control box that interfaces directly with USB-based AV equipment. The simplified mounting options for wall, inverted National Pipe Thread (NPT) mounting and tripods along with discreet cable routing enable efficient and professional looking installations. The solution leveraging Rally Camera, and its USB based technology, seamlessly works with most operating systems, as well as the most popular video collaboration and lecture capture platforms making it a versatile addition to any presentation environment.

Pricing and availability

Logitech Rally Camera Streamline Kit which includes the Rally Camera, the Extension Kit, the mounts and three preset buttons will be available to pre-order spring 2025 via channel partners at a suggested retail price of $2199. The Extension Kit, individual mounts and individual buttons will also be available for sale as add-ons for the Rally Camera. Learn more about Rally Camera Streamline Kit by visiting http://www.rallycamstreamlinekit.com.

About Logitech

Logitech designs software-enabled hardware solutions that help businesses thrive and bring people together when working, creating, gaming and streaming. As the point of connection between people and the digital world, our mission is to extend human potential in work and play, in a way that is good for people and the planet. Founded in 1981, Logitech International is a Swiss public company listed on the SIX Swiss Exchange (LOGN) and the Nasdaq Global Select Market (LOGI). Find Logitech and more of its business products and enterprise solutions at www.logitech.com/business, the company blog, Logitech Business or @LogitechBiz.

Logitech and other Logitech marks are trademarks or registered trademarks of Logitech Europe S.A. and/or its affiliates in the U.S. and other countries. All other trademarks are the property of their respective owners. For more information about Logitech and its products, visit the company’s website at www.logitech.com

Media contact:

Wendy Spander, Logitech Global Communications

1-510-713-5393

[email protected]

KEYWORDS: Europe Switzerland United States North America California

INDUSTRY KEYWORDS: Software Technology Photography Hardware

MEDIA:

Logo
Logo
Photo
Photo
Introducing the Logitech Rally Camera Streamline Kit, a comprehensive USB Pan Tilt Zoom (PTZ) video solution for hyflex learning (Photo: Business Wire)
Posted on

BioWorld by Clarivate Releases Comprehensive 2024 Year in Review

PR Newswire

Series Recaps Biopharma, MedTech, and Science Trends and Breakthroughs That Shaped the Year


LONDON
, Jan. 16, 2025 /PRNewswire/ — BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has released its highly anticipated 2024 Year in Review series. This multipart special report offers an in-depth analysis of the therapeutic trends, regulatory actions and economic shifts that defined biopharma, med tech and scientific innovation over the past year while forecasting key developments for 2025.

As the biopharma and med-tech industries continue to evolve, 2024 proved to be a landmark year. The comprehensive recap by BioWorld highlights therapeutic breakthroughs in psychiatry, oncology, women’s health and infectious diseases, alongside economic highs and lows that challenged the global landscape. The series also examines regulatory changes, including U.S. court cases and international policy shifts, that could shape the future of drug pricing, reimbursement, and innovation.


Lynn Yoffee, Publisher of BioWorld, said: “The 2024 Year in Review series provides a powerful lens into the transformative events and advancements that shaped our industry this year. With our team of expert journalists and analysts, we strive to distill complex developments into actionable insights, empowering stakeholders to make informed decisions as they navigate 2025 and beyond.”

Key Highlights of the BioWorld 2024 Year in Review Series:


BioWorld Year in Review

: This section highlights the top mergers and acquisitions, licensing deals, financings, and first approvals of 2024. It also provides insights into key therapeutic trends such as GLP-1 receptor agonists, antibody-drug conjugates (ADCs), psychedelics, and the evolving role of precision psychiatry, alongside innovations spurred by the pandemic. Featured articles include:

  • The Economy: Top Biopharma Trends of 2024 by Amanda Lanier 
    A comprehensive infographic that highlights how 2024 showcased resilience amidst challenges, with biopharma financing and deal values rebounding significantly despite over 18,000 job losses and a tempered IPO market. Spotlights include record-high deal values, a steady M&A pace with reduced total value, and a slightly increased rate of workforce reductions compared to 2023.
  • Year’s top US court cases to present new challenges for 2025 by Mari Serebrov
    The Loper Bright decision ended the Chevron doctrine, curbing agency authority and reshaping regulatory dynamics for 2025. Meanwhile, Gilead’s $40 million settlement over HIV drug delays highlights new liability risks for biopharma. Both developments underscore the evolving legal landscape and its potential to reshape regulatory and innovation dynamics in 2025.
  • European VC improves in 2024, driven by ADCs and CNS, inflammatory drugs by Nuala Moran
    European biotech funding improved in 2024, with venture capital raised exceeding 2020 levels but still trailing the pandemic peak. Investors favored later-stage programs with clearer paths to exits, while antibody-drug conjugates (ADCs) and central nervous system (CNS) assets drew significant interest. Despite challenges like closed public markets and antimicrobial fragility, optimism for 2025 is growing, fueled by expected macroeconomic improvements and strong M&A activity.
  • GLP-1 receptor agonists continue their global victory tour by Anette Breindl
    GLP-1 receptor agonists (GLP-1RAs) had a transformative 2024, expanding into new therapeutic indications, including FDA approval for treating obstructive sleep apnea in adults with obesity, while continuing to demonstrate benefits in cardiovascular health, kidney disease, and other conditions. Despite their success, GLP-1RAs remain treatments rather than cures for underlying conditions like diabetes, prompting ongoing research into root-cause solutions.


BioWorld MedTech Year in Review

: This section recaps key med-tech and diagnostic breakthroughs, covering cutting-edge advancements in brain mapping and pregnancy health, as well as regulatory developments expected to impact the sector in 2025. Coverage includes: 

  • AI drives financings, approvals for APAC med-tech in 2024 By Marian (YoonJee) Chu
    In 2024, AI spurred significant financings and approvals in APAC med-tech, leveraging regional strengths like talent pools, data infrastructure, and government support. Key highlights included AI-powered IPOs, billion-dollar pharma collaborations, and national investments, solidifying APAC’s role in AI-driven healthcare innovation.
  • Medicare coverage issues abound in 2024 by Mark McCarty
    In 2024, Medicare faced challenges in covering emerging technologies, with the new TCET policy offering limited scope. Coverage for digital health and SaaS remained stalled due to outdated benefit categories. Meanwhile, Medicare’s reimbursement rates for radiation oncology and skin substitutes sparked controversy.


BioWorld Science Year in Review

: This section explores key research milestones, featuring global collaborations in infectious diseases, breakthroughs in curable tumors and innovations in women’s health and neuroscience. Key highlights include:

  • The map for a journey to the center of the brain by Mar de Miguel
    The year 2024 marks a milestone with the end of a long journey: a complete cellular map of the fruit fly brain, Drosophila melanogaster, and a cubic millimeter of the human brain. The adventure is just beginning for the thinking species Homo sapiens.
  • Progress in cancer research, even the toughest types by Mar de Miguel and Anette Breindl
    Among the most profound results presented at the 2024 European Society for Medical Oncology  Congress were the 10-year data from the Checkmate-067 and Keynote-006 trials, the phase III trials that tested Opdivo (nivolumab, Bristol Myers Squibb Co.) and Keytruda (pembrolizumab, Merck & Co. Inc.) as first-line agents in advanced or metastatic melanoma.

The series also includes the BioWorld editorial picks for the “Best of 2024,” dynamic infographics summarizing key data, and a global perspective on funding and policy changes across Europe and Asia.

To access the full BioWorld special series, visit https://www.bioworld.com/special_reports.  

Join the conversation and mention BioWorld on X and LinkedIn as well as Clarivate for Life Sciences & Healthcare on X and LinkedIn. 

About BioWorld
With writers and editors stationed around the globe, BioWorld published by Clarivate, reports the breaking news – and provides key perspective on thousands of therapeutics and devices in development, the companies behind those candidates, the business development transactions that evolve the markets, and the regulatory hurdles that both challenge and guard the processes. BioWorld has a long tradition of excellence in journalism. Collectively, the news services have been honored with 70 awards dating back to 1998.

About Clarivate

Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.Clarivate.com.

Media Contact:

Catherine Daniel

Director, External Communications, Life Sciences & Healthcare
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bioworld-by-clarivate-releases-comprehensive-2024-year-in-review-302352663.html

SOURCE Clarivate Plc

Posted on

Pearson 2024 Trading Update (Unaudited)

Pearson 2024 Trading Update (Unaudited)

Delivered on financial1 and strategic priorities for 2024. Entering 2025 with continued confidence. New strategic partnership with Microsoft progressing our Enterprise focus and technology transformation.

LONDON–(BUSINESS WIRE)–Highlights

  • Underlying Group sales growth2 of 3% for the full year, excluding OPM3 and the Strategic Review4 businesses.
  • Group adjusted operating profit of £595-600m at £:$ of 1.28 for the full year, up c.10% on an underlying basis compared to 2023, resulting in a margin of c.16.8% (2023: 15.6%).
  • Free cash flow conversion in excess of 100%5, ahead of guidance.
  • Successfully delivered our 2024 strategic priorities with progress in Enterprise and scaling AI across our products and services including the recent launch of an AI powered Digital Language Tutor (link here).
  • New multi-year strategic Enterprise AI partnership with Microsoft (link here):
    • Extending our commercial relationship with Pearson VUE;
    • Future collaboration on innovation and joint go-to-market activities, including in AI upskilling; and
    • Opportunity to enhance our AI and technology capabilities across the business.

Omar Abbosh, Pearson’sChief Executive, said:

“I am pleased with the progress Pearson has made in 2024, successfully executing against our financial and strategic priorities. I’m particularly encouraged to see the growing commercial momentum of our AI enhanced offerings and the strategic Enterprise partnerships that we have established, such as the latest with Microsoft. These reflect the strength of our proposition and the opportunities that lie ahead.

The Group is well positioned, with continued confidence, as we look to build on our strategic and operational progress and deliver long-term future value for our shareholders.”

Underlying sales growth2 of 3% for 2024, excluding OPM3 and Strategic Review4 businesses; 2% in aggregate

  • Assessment & Qualifications sales were up 3% for the full year and 4% in Q4. Pearson VUE performance was driven by favourable mix, with PDRI seeing good growth. In Clinical Assessment, sales grew due to pricing, digital product growth and successful new product launches. UK & International Qualifications benefited from volume, pricing, and International growth. US Student Assessment performance was supported by several key contract renewals.

  • Virtual Schools sales decreased 1% for the full year, due to the previously announced partner school losses, the impact of which will normalise in H1 2025. 2024/25 academic year enrolments were up 4% on a same school basis and we opened 3 new schools in 2024 taking our total number of schools to 40. Virtual Learning sales declined 4% for the full year attributable to the final portion of the OPM ASU contract in the first half of 2023. Virtual Learning sales declined 5% in Q4 as expected, driven by a tough comparator which saw funding improvements in Virtual Schools in 2023

  • Higher Education sales grew 1% for the full year and 2% in Q4, in line with expectations. In US Higher Education full year sales growth was driven by continued gains in adoption share, enrolments, and pricing, partially offset by mix impacts. In the year, there was growth of 3% in US digital subscriptions and 24% in Inclusive Access. We accelerated the rollout of AI within our products in the fourth quarter. Pearson+ registered users increased 1% compared to the prior Fall semester, with paid subscriptions flat over the same period and in addition we have been successful in monetising our Channels product.

  • English Language Learning sales increased 8% for the full year with all three business sub-units contributing to growth. Institutional continues to deliver strong performance especially in the Middle East and LatAm. Pearson Test of English (PTE) performed well against a tough market backdrop of tightening migration policies. We continue to incorporate AI within our English Language business unit, launching our first AI powered Digital Language Tutor in the fourth quarter. In Q4 sales grew 11%, an improvement on Q3 due to phasing of revenue in Institutional as expected.

  • Workforce Skills sales grew 6% for the full year, with a solid performance in both Vocational Qualifications and Workforce Solutions. Q4 sales increased by 4% driven by a strong performance in Workforce Solutions partially offset by Vocational Qualifications, as the business had a tough comparator with strong double digit growth in the prior year.

Evolution of Workforce Skills

  • Pearson has a significant opportunity to help enterprises drive productivity and growth by transforming how they evaluate, assess, and reskill their workforce, as well as delivering world-class vocational training and qualifications. To sharpen our focus on the enterprise customer segment, we have formed a global enterprise sales team to enable us to better meet the needs of these customers with a full suite of Pearson solutions. From January this year, Workforce Skills will evolve to become Enterprise Learning and Skills, bringing together Pearson’s enterprise sales capabilities globally (excluding those of Pearson VUE). The Enterprise Learning and Skills business unit will be led by Vishaal Gupta.

  • This simplification of the business unit structure will result in modest revenues and costs being transitioned into the Enterprise Learning and Skills business unit from Higher Education. More detail on the financial impact of this change will be outlined at the full year results. We also note that the sub-unit Workforce Solutions becomes Enterprise Solutions.

Strong financial position

  • Pearson’s financial position remains robust, with a strong balance sheet, net debt of less than £0.9bn and 2024 free cash flow conversion in excess of 100%5.

Executive Changes

  • We announce the appointment of Naseem Tuffaha as Chief Business Officer. Naseem has a successful track record of high growth and operational excellence at Microsoft, and more recently The Trade Desk.

Financial calendar

  • Full year results will be announced on 28 February 2025. We will hold an in-person presentation and Q&A session, during which we will outline the 2025 outlook.

Financial summary

Underlying growth for the fourth quarter and financial year ended 31st December 2024 compared to the equivalent period in 2023.

Sales

Q4

Full Year

Assessment & Qualifications

4%

3%

Virtual Learning

(5)%

(4)%

Higher Education

2%

1%

English Language Learning

11%

8%

Workforce Skills

4%

6%

Strategic Review4

(100)%

(100)%

Total

3%

2%

Total, excluding OPM3 and Strategic Review4

3%

3%

For an accompanying data sheet providing 2024 metrics relating to sales across select key businesses as well as a breakdown of US Higher Education Courseware college units and Pearson+ metrics, please follow this link.

1 2024 consensus on the Pearson website dated 30th August 2024; adjusted operating profit of £598m at £:$ 1.27. As a reminder, every 1c movement in £:$ rate will equate to approximately £5m adjusted operating profit impact.

2 Throughout this announcement growth rates are stated on an underlying basis unless otherwise stated. Underlying growth rates exclude currency movements, and portfolio changes.

3 We completed the sale of the Pearson Online Learning Services (POLS) business in June 2023 and as such have removed it from underlying measures throughout. Within this specific measure we exclude our entire OPM business (POLS and ASU) to aid comparison to guidance.

4 Strategic Review is sales in international courseware local publishing businesses which have been wound down. As expected, there are no sales in these businesses in 2024.

5 Free cash flow conversion calculated as free cash flow divided by adjusted earnings.

About Pearson

At Pearson, our purpose is simple: to help people realise the life they imagine through learning. We believe that every learning opportunity is a chance for a personal breakthrough. That’s why our Pearson employees are committed to creating vibrant and enriching learning experiences designed for real-life impact. We are the world’s lifelong learning company, serving customers with digital content, assessments, qualifications, and data. For us, learning isn’t just what we do. It’s who we are. Visit us at pearsonplc.com.

Notes

Forward looking statements: Except for the historical information contained herein, the matters discussed in this statement include forward-looking statements. In particular, all statements that express forecasts, expectations and projections with respect to future matters, including trends in results of operations, margins, growth rates, overall market trends, the impact of interest or exchange rates, the availability of financing, anticipated cost savings and synergies and the execution of Pearson’s strategy, are forward-looking statements. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that will occur in future. They are based on numerous assumptions regarding Pearson’s present and future business strategies and the environment in which it will operate in the future. There are a number of factors which could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements, including a number of factors outside Pearson’s control. These include international, national and local conditions, as well as competition. They also include other risks detailed from time to time in Pearson’s publicly-filed documents and you are advised to read, in particular, the risk factors set out in Pearson’s latest annual report and accounts, which can be found on its website (www.pearsonplc.com). Any forward-looking statements speak only as of the date they are made, and Pearson gives no undertaking to update forward-looking statements to reflect any changes in its expectations with regard thereto or any changes to events, conditions or circumstances on which any such statement is based. Readers are cautioned not to place undue reliance on such forward-looking statements.

Investor Relations

Alex Shore +44 (0) 7720 947 853

Gemma Terry +44 (0) 7841 363 216

Steph Crinnegan +44 (0) 7780 555 351

Brennan Matthews +1 (332) 238-8785

Media

Teneo

Ed Cropley +44 (0) 7492 949 346

Pearson

Laura Ewart +44 (0) 7798 846 805

KEYWORDS: United Kingdom Europe

INDUSTRY KEYWORDS: Technology Finance Professional Services Internet Continuing Training University Data Management Education

MEDIA:

Logo
Logo
Posted on

IBM and L’Oréal to Build First AI Model to Advance the Creation of Sustainable Cosmetics

PR Newswire


PARIS and NEW YORK, Jan. 16, 2025 /PRNewswire/ — IBM (NYSE: IBM) and L’Oréal, the world’s leading beauty company, announced a collaboration to leverage IBM’s generative artificial intelligence (GenAI) technology and expertise to uncover new insights in cosmetic formulation data, facilitating L’Oréal’s use of sustainable raw materials, for energy and material waste reductions. This unique effort will develop a custom AI foundation model engineered to significantly increase the ability of L’Oréal Research & Innovation teams to reach extra performance and consumer satisfaction in every cosmetic category and every region of the world. The formulation foundation model is believed to be a first-of-its-kind in the industry, redefining AI innovation at the intersection of beauty, chemistry and technology. 

The collaboration combines L’Oréal’s unparalleled expertise in cosmetic science with IBM’s cutting-edge artificial intelligence technologies for scientific discoveries, to unlock a future where science and technology can inform or help prioritize solutions that are both ecologically responsible and innovative. To preserve Earth’s natural resources, it is critical to explore renewable, sustainably sourced raw materials when developing consumer products. This effort will contribute to helping L’Oréal meet its L’Oréal for the Future’s target of sourcing most of its product formulas based on bio-sourced materials and/or the circular economy by 2030. 

“As part of our Digital Transformation Program, this partnership will extend the speed and scale of our innovation and reformulation pipeline, with products always reaching higher standards of inclusivity, sustainability, and personalization”, declares Stéphane Ortiz, Head of Innovation Métiers & Product Development – L’Oréal Research & Innovation.

“Building on years of unique Beauty science expertise and of data structuring, this major alliance with IBM is opening a new exciting era for our innovation and development process”, said Matthieu Cassier, Chief Transformation & Digital Officer – L’Oréal Research & Innovation.

“This collaboration is a truly impactful application of generative AI, leveraging the power of technology and expertise for the good of the planet”, said

Alessandro Curioni, IBM Fellow, Vice President Europe and Africa and Director IBM Research Zurich
. “At IBM, we believe in the power of purpose-built, customized AI to help transform businesses. Using IBM’s latest AI technology, L’Oréal will be able to derive meaningful insights from their rich formula and product data to create a tailored AI model to help achieve their operational goals and continue creating high quality and sustainable products.”

“This alliance between highly specialized expertise in artificial intelligence and cosmetics seeks to revolutionize cosmetic formulation. It embodies the spirit of AI-augmented research, emphasizing sustainability and diversity”, declares
Guilhaume Leroy-Méline, IBM Distinguished Engineer, Business Transformation Services CTO, IBM Consulting France
.

The creation of this AI model will use a large number of formulations and component data points to accelerate multiple tasks to be performed by L’Oréal, including the formulation of new products, reformulation of existing cosmetics and optimization for scale-up production – tools that will better equip L’Oréal’s 4,000 researchers worldwide over the next several years. In addition, IBM Consulting will support L’Oréal in its aim to rethink and redesign the formulation discovery process. Understanding the behaviors of renewable ingredients in cosmetic formulas will help L’Oréal build out more sustainable product lines with greater inclusivity and personalization for its consumers around the world. 

Foundation models are a type of AI model trained on a broad set of unlabeled data, capable of performing various tasks and applying information from one situation to another. These models have significantly advanced the field of natural language processing (NLP) technology over the past several years, and IBM is pioneering applications of foundation models beyond language, in areas such as chemistry, time series and geospatial modalities. IBM’s AI technology has the potential to augment L’Oréal’s creativity in finding new cosmetic formulations to transform the beauty industry. L’Oréal, together with IBM’s expertise and technology, will help to shape a future where innovation meets sustainability, delivering products that will be as unique as the people who use them daily. 

About L’Oréal  

For 115 years, L’Oréal, the world’s leading beauty player, has devoted itself to one thing only: fulfilling the beauty aspirations of consumers around the world. Our purpose, to create the beauty that moves the world, defines our approach to beauty as essential, inclusive, ethical, generous and committed to social and environmental sustainability. With our broad portfolio of 37 international brands and ambitious sustainability commitments in our L’Oréal for the Future programme, we offer each and every person around the world the best in terms of quality, efficacy, safety, sincerity and responsibility, while celebrating beauty in its infinite plurality.  

With more than 90,000 committed employees, a balanced geographical footprint and sales across all distribution networks (e-commerce, mass market, department stores, pharmacies, perfumeries, hair salons, branded and travel retail), in 2023 the Group generated sales amounting to 41.18 billion euros. With 20 research centers across 11 countries around the world and a dedicated Research and Innovation team of over 4,000 scientists and 6,400 Digital talents, L’Oréal is focused on inventing the future of beauty and becoming a Beauty Tech powerhouse.  

More information on https://www.loreal.com/en/mediaroom 

About IBM 

IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. More than 4,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM’s long-standing commitment to trust, transparency, responsibility, inclusivity and service. Visit www.ibm.com 

Contacts :

Brittany Forgione

IBM
[email protected]

Stéphanie Glemot
IBM France
[email protected] 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ibm-and-loreal-to-build-first-ai-model-to-advance-the-creation-of-sustainable-cosmetics-302352463.html

SOURCE IBM

Posted on

Avast Expands Identity Protection Solution to Help Tackle Rise in Scam and Identity Theft

PR Newswire

Avast debuts Avast Secure Identity to 15 new countries outside of the US


TEMPE, Ariz. and PRAGUE, Jan. 16, 2025 /PRNewswire/ — Avast, a leader in digital security and privacy and part of Gen™ (NASDAQ: GEN), has expanded the availability of its identity protection solution, Avast Secure Identity, to help people around the world keep their identity safer from escalating scam and identity theft risks.

Over the past year, there’s been a surge in large-scale data breaches. These breaches are an opportunity for cybercriminals to take over peoples’ identities by stitching together personal data from breaches with other information from public sources. The risk of identity theft increases as criminals attempt to break into devices using carefully crafted social engineering attacks that manipulate people into making security mistakes or divulging their private information. The recent Q3/2024 Gen Threat Report highlighted a 614% increase in “Scam-Yourself Attacks,” where cybercriminals use psychological manipulation tactics to trick people into installing malware on their own devices, allowing them to gain access. Avast Secure Identity combined with Avast antivirus provides comprehensive protection against identity theft and other threats like Scam-Yourself Attacks that can lead to it.

“Identity theft is on the rise, and as the severity and frequency of data breaches increases, cybercriminals will continue to use the personal information they have access to in even more sophisticated ways,” said Leena Elias, Chief Product Officer at Gen. “Identity theft has no borders. It can happen to anyone, anywhere, and potentially cause lasting financial and reputational harm. If the worst happens, the process of restoring somebody’s identity is often exhausting. We’ve expanded the availability of Avast Secure Identity so that more people around the world can better protect their identities and receive the support they need to restore them if they fall victim.”

Avast Secure Identity continuously monitors for personal information across private forums and the deep and dark web and notifies customers if any of their personal information is detected. Personalized guidance from knowledgeable Identity Restoration Specialists gives people peace of mind if identity theft occurs. 

Key features available in Avast Secure Identity include:

  • Dark Web Monitoring: Continuously scans dark web sites and forums, notifying people if their personal information such as credit card and passport numbers is found.
  • Social Media Monitoring: Monitors popular social media accounts, notifying users of compromised accounts or risky links.
  • Restoration Support: Offers access to Identity Restoration Specialists who guide victims of identity theft through the recovery process, including mediation and disputing fraudulent activities.
  • Stolen Wallet Assist: Helps people by guiding them on how to cancel or replace key documents like credit cards and driver’s licenses if their wallet is stolen.
  • Financial Monitoring: Tracks recurring subscriptions and alerts people to suspicious transactions on bank accounts that may indicate fraud. Currently available in the UK, Australia and New Zealand.
  • Identity Theft Insurance: Provides coverage for specific expenses and losses, including legal expense reimbursement and lost income for time away from work to correct financial records, due to identity theft. Currently available in Australia and New Zealand only.

Avast Secure Identity is now available in 15 additional countries outside of the US, including the UK, France, Germany, Australia, New Zealand, Brazil, Mexico, Spain and Italy. For more information, please visit: https://www.avast.com/en-gb/secure-identity.

AVG, a leader in software security products and part of Gen, has also expanded its Secure Identity product to these countries with these identity protection capabilities.  

Insurance Disclaimers:

Australia: Terms, conditions, exclusions and limitations apply, see the Identity Theft Insurance Australia Policy Information Booklet found on https://www.nortonlifelock.com/au/en/legal/ for details.
New Zealand: Terms, conditions, exclusions and limitations apply, see the Identity Theft Insurance New Zealand Policy Information Booklet found on https://www.nortonlifelock.com/aa/en/legal/ for details.

About Avast

Avast is a leader in digital security and privacy, and part of Gen™ (NASDAQ: GEN), a global company dedicated to powering Digital Freedom with a family of trusted consumer brands. Avast protects hundreds of millions of users from online threats, for Mobile, PC or Mac, and is top-ranked and certified by VB100, AV-Comparatives, AV-Test, SE Labs and others. Avast is a member of the Coalition Against Stalkerware, No More Ransom and Internet Watch Foundation. Learn more at Avast.com.

About AVG
AVG is a leader in software security products for families and individuals who want carefree connected living, and part of Gen™, a global company dedicated to powering Digital Freedom with a family of trusted consumer brands. AVG has an award-winning consumer portfolio including internet security, performance optimization, location services, data controls and insights, and privacy and identity protection, for PCs and mobile devices.  AVG products and services are continuously rated best-in-class by VB100, AV-Comparatives, and AV-TEST. Learn more at AVG.com.

Mike Healey 

Allie Thompson

Gen


[email protected] 

Edelman for Gen


[email protected] 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/avast-expands-identity-protection-solution-to-help-tackle-rise-in-scam-and-identity-theft-302352635.html

SOURCE Gen Digital Inc.

Posted on

Stellantis Reports Q4 2024 Consolidated Shipment Estimates

Stellantis Reports Q4 2024 Consolidated Shipment Estimates


-9% Q4 y-o-y decline in shipments improved vs. -20% in Q3, as inventory reduction actions concluded and new product launches in Europe reduced gaps in the Company’s offering related to our generational portfolio transition 

AMSTERDAM, January 16, 2025 – Stellantis N.V. today published global quarterly consolidated shipment estimates and provided commentary on related business trends. The term shipments describes volumes of vehicles delivered to our dealers, distributors, or directly from the Company to retail and fleet customers, which directly drive revenue recognition.

Consolidated shipments for the three months ending December 31, 2024, were an estimated 1,395 thousand units, representing a 9% decline versus the same period in 2023. The shipment performance directionally converged with the underlying sales performance in the period of approximately -5%, as U.S. inventory reduction initiatives concluded successfully and shipments in Europe were supported by the launch of certain next-generation products which reduced a temporary gap in the production of certain Stellantis products in the region.

  • In North America, Q4 shipments declined approximately 115 thousand units vs the same period in 2023, representing a 28% y-o-y decline, in contrast to a more modest sales decline of 5% y-o-y. The larger decline in shipments reflected inventory reduction initiatives, where production discipline combined with incentive actions resulted in a ~80K units decrease of the U.S. dealer inventory compared to the end of the Q3, ending the period just over 300K units. The normalization of the U.S. dealer inventory puts the Company in a strong position to support the arrival of new products in 2025 from Jeep, Ram and Dodge.
  • In Enlarged Europe, the 6% y-o-y shipment decline in Q4 was strongly reduced compared to Q3 (-17% y-o-y) as a temporary gap in certain B-segment offerings was substantially reduced due to the launch of the Citroën C3/ë-C3. Additional B-segment products will soon follow, such as the MHEV Citroën C3, as well as the multi-energy Citroën C3 Aircross, Opel Frontera, and Fiat Grande Panda offerings. The initial European product launches of Stellantis’ next-generation product wave is seeing a promising start, with orders received for over 90K units for the Citroën C3/ë-C3, and over 140K units for the initial STLA Medium platform Peugeot 3008, Peugeot 5008 and Opel Grandland.
  • In Stellantis’ “Third Engine”(2), shipments grew by 5% driven by a 12% increase in South America and a stable Middle East & Africa, more than offsetting shipment declines in China and India & Asia Pacific. South America shipments were supported by a stronger industry demand in all main markets and an ongoing production recovery following the Rio Grande do Sul flooding. Middle East & Africa shipments were stable, reflecting improvement in Turkey, Morocco, Egypt and Tunisia, mostly offset by the impact of temporary import restrictions in Algeria.

(1)   Consolidated shipments only include shipments by Company’s consolidated subsidiaries, which represent new vehicles invoiced to third party (dealers/importers or final customers). 

Consolidated shipment volumes for Q4 2024 presented here are unaudited and may be adjusted. Final figures will be provided in our official revenue/shipments report. Analysts should interpret these numbers with the understanding that they are preliminary and subject to change.

(2)   The “Third Engine” refers to the aggregation of the South America, Middle East & Africa and China and India & Asia Pacific segments for presentation purposes only.

# # #


About Stellantis

Stellantis N.V. (NYSE: STLA / Euronext Milan: STLAM / Euronext Paris: STLAP) is one of the world’s leading automakers aiming to provide clean, safe and affordable freedom of mobility to all. It’s best known for its unique portfolio of iconic and innovative brands including Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, FIAT, Jeep

®

, Lancia, Maserati, Opel, Peugeot, Ram, Vauxhall, Free2move and Leasys. Stellantis is executing its Dare Forward 2030, a bold strategic plan that paves the way to achieve the ambitious target of becoming a carbon net zero mobility tech company by 2038, with single-digit percentage compensation of the remaining emissions, while creating added value for all stakeholders. For more information, visit


www.stellantis.com

.

@Stellantis Stellantis Stellantis Stellantis

For more information, contact:

[email protected]

[email protected]
www.stellantis.com

  



Stellantis Forward Looking Statements
 
  
This communication contains forward-looking statements. In particular, statements regarding future events and anticipated results of operations, business strategies, the anticipated benefits of the proposed transaction, future financial and operating results, the anticipated closing date for the proposed transaction and other anticipated aspects of our operations or operating results are forward-looking statements. These statements may include terms such as “may”, “will”, “expect”, “could”, “should”, “intend”, “estimate”, “anticipate”, “believe”, “remain”, “on track”, “design”, “target”, “objective”, “goal”, “forecast”, “projection”, “outlook”, “prospects”, “plan”, or similar terms. Forward-looking statements are not guarantees of future performance. Rather, they are based on Stellantis’ current state of knowledge, future expectations and projections about future events and are by their nature, subject to inherent risks and uncertainties. They relate to events and depend on circumstances that may or may not occur or exist in the future and, as such, undue reliance should not be placed on them. 

Actual results may differ materially from those expressed in forward-looking statements as a result of a variety of factors, including: the ability of Stellantis to launch new products successfully and to maintain vehicle shipment volumes; changes in the global financial markets, general economic environment and changes in demand for automotive products, which is subject to cyclicality; Stellantis’ ability to successfully manage the industry-wide transition from internal combustion engines to full electrification; Stellantis’ ability to offer innovative, attractive products and to develop, manufacture and sell vehicles with advanced features including enhanced electrification, connectivity and autonomous-driving characteristics; Stellantis’ ability to produce or procure electric batteries with competitive performance, cost and at required volumes; Stellantis’ ability to successfully launch new businesses and integrate acquisitions; a significant malfunction, disruption or security breach compromising information technology systems or the electronic control systems contained in Stellantis’ vehicles; exchange rate fluctuations, interest rate changes, credit risk and other market risks; increases in costs, disruptions of supply or shortages of raw materials, parts, components and systems used in Stellantis’ vehicles; changes in local economic and political conditions; changes in trade policy, the imposition of global and regional tariffs or tariffs targeted to the automotive industry, the enactment of tax reforms or other changes in tax laws and regulations; the level of governmental economic incentives available to support the adoption of battery electric vehicles; the impact of increasingly stringent regulations regarding fuel efficiency requirements and reduced greenhouse gas and tailpipe emissions; various types of claims, lawsuits, governmental investigations and other contingencies, including product liability and warranty claims and environmental claims, investigations and lawsuits; material operating expenditures in relation to compliance with environmental, health and safety regulations; the level of competition in the automotive industry, which may increase due to consolidation and new entrants; Stellantis’ ability to attract and retain experienced management and employees; exposure to shortfalls in the funding of Stellantis’ defined benefit pension plans; Stellantis’ ability to provide or arrange for access to adequate financing for dealers and retail customers and associated risks related to the operations of financial services companies; Stellantis’ ability to access funding to execute its business plan; Stellantis’ ability to realize anticipated benefits from joint venture arrangements; disruptions arising from political, social and economic instability; risks associated with Stellantis’ relationships with employees, dealers and suppliers; Stellantis’ ability to maintain effective internal controls over financial reporting; developments in labor and industrial relations and developments in applicable labor laws; earthquakes or other disasters; risks and other items described in Stellantis’ Annual Report on Form 20-F for the year ended December 31, 2023 and Current Reports on Form 6-K and amendments thereto filed with the SEC; and other risks and uncertainties. 

Any forward-looking statements contained in this communication speak only as of the date of this document and Stellantis disclaims any obligation to update or revise publicly forward-looking statements. Further information concerning Stellantis and its businesses, including factors that could materially affect Stellantis’ financial results, is included in Stellantis’ reports and filings with the U.S. Securities and Exchange Commission and AFM. 

Attachment



Posted on

Broadridge Enhances Multi-Asset Post Trade Processing with GenAI-Powered Analytics

PR Newswire


NEW YORK and LONDON and TOYKO, Jan. 16, 2025 /PRNewswire/ — To better streamline multi-asset post-trade processing and operational reporting, Broadridge Financial Solutions Inc. (NYSE: BR), a global Fintech leader, today announced it added an GenAI-powered advanced analytics feature to its platform. A key component of the Broadridge’s OpsGPT ® application, this new GenAI-powered functionality enables users to generate insights and visualizations directly from their trade data using natural language, eliminating the need for data migration.

“Integrating this AI advanced analytics feature into our post-trade platform delivers simplification and innovation, significantly improving risk management and operational efficiency, especially in response to growing regulatory demands,” said Danny Green, head of international post-trade at Broadridge. “The multilingual capabilities and seamless integration provide an accessible solution for broker-dealers and banks, allowing them to quickly access actionable insights without the complexity of traditional reporting tools.”

This new feature, part of Broadridge’s OpsGPT, leverages generative AI and natural language interactions to supply instant reports, data visualization and quickly generated summaries in an intuitive and user-friendly interface. A key benefit of the new feature is its ability to reduce reliance on manual reporting, replacing it with an AI-driven analytics tool that supports multiple languages, including English and Japanese, with plans for Chinese capability in the near future.

The advanced analytics feature is instrumental to international firms navigating evolving regulatory and market dynamics. By streamlining reporting tasks, the tool enables current and prospective post-trade platform users across EMEA and APAC to better manage their operations and maintain compliance, while addressing the challenges posed by faster settlement cycles and compressed margins.

The feature underscores Broadridge’s data and AI strategy and commitment to innovating to enhance user productivity, capabilities and compliance. With faster and deeper data analytics, users can swiftly identify and rectify anomalies, employing predictive analytics to anticipate and mitigate potential bottlenecks.

For more information on streamlining post-trade operations, please see here.

About Broadridge

Broadridge Financial Solutions (NYSE: BR), is a global technology leader with the trusted expertise and transformative technology to help clients and the financial services industry operate, innovate, and grow. We power investing, governance, and communications for our clients – driving operational resiliency, elevating business performance, and transforming investor experiences. 

Our technology and operations platforms underpin the daily trading of more than $10 trillion of equities, fixed income and other securities globally. A certified Great Place to Work®, Broadridge is part of the S&P 500® Index, employing over 14,000 associates in 21 countries. For more information about us, please visit www.broadridge.com. 

Broadridge Contacts:

Investors: 
Edings Thibault
Head of Investor Relations, Broadridge
[email protected] 

Media:

Gregg Rosenberg

Global Head of Corporate Communications
[email protected] 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/broadridge-enhances-multi-asset-post-trade-processing-with-genai-powered-analytics-302352626.html

SOURCE Broadridge Financial Solutions, Inc.

Posted on

Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024

Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024

MARSEILLE, France–(BUSINESS WIRE)–
Regulatory News:

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as of December 31, 2024:

Total number of shares outstanding:

83,830,336

ordinary shares

 

6,494

Preferred Shares 2016

7,581

Preferred Shares 2017

 

 

Total number of theoretical voting rights (1):

84,585,576

Total number of exercisable voting rights (2):

84,567,001

(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP 2017.

(2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).

Innate’s portfolio includes several ANKET® drug candidates to address multiple tumor types as well as IPH4502 a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

ISIN code

Ticker code

LEI

FR0010331421

Euronext: IPH Nasdaq: IPHA

9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “expect” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:


Investors


Innate Pharma

Henry Wheeler

Tel.: +33 (0)4 84 90 32 88

[email protected]

Media Relations


NewCap

Arthur Rouillé

Tel.: +33 (0)1 44 71 00 15

[email protected]

KEYWORDS: Europe United States North America France

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Finance Oncology General Health Health Professional Services Clinical Trials

MEDIA:

Logo
Logo
Posted on

Introducing Lee® X: An Innovative Platform that Redefines Men’s Apparel

Introducing Lee® X: An Innovative Platform that Redefines Men’s Apparel

Capsule Addresses Comfort, Stretch and Breathability in Pieces that Elevate Everyday Essentials

GREENSBORO, N.C.–(BUSINESS WIRE)–
Today, Lee, the iconic American brand known for timeless style and innovative fit solutions, launches Lee X, an exciting product platform that incorporates the latest in fabric technology and modern design.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250115121874/en/

The new Lee X platform incorporates the latest fabric and design innovations into performance-based modern styles. Photo Credit: ©Lee

The new Lee X platform incorporates the latest fabric and design innovations into performance-based modern styles. Photo Credit: ©Lee

The Lee X platform expands upon the brand’s best-selling Extreme Motion line, which introduced stretch fabric and flex waistbands to men’s denim nine years ago. Lee X hallmarks those features and incorporates new ones designed for comfort and performance. Key features include an updated gusset for movement, premium fabrics with TruTemp™365® technology and moisture-wicking, and being responsibly crafted with sustainable details like a patch made from recycled apple skins.

“We’ve been working tirelessly developing Lee X to bring game-changing innovation to our consumers, so I’m excited to see these products in market,” said Jimmy Shafer, global vice president for Lee. “The jeans are built on a foundation of performance fabrics, but engineered to retain that true denim feel. And the casual pants are incredibly versatile; you’ll want to wear them everywhere. I’m confident that Lee X is creating a new value equation in the market and that these styles will become new favorites of our current loyalists while attracting new consumers to the brand.”

Lee X is available in three different collections and complementing tops:

  • Lee X Move: Designed to Move

    Lee X Move delivers the ultimate fit and feel for all day wear in both denim and non-denim options. Jeans are crafted with premium easy-care fabric that stretches yet retains its shape and the classic denim feel. TruTemp365® technology helps keep you comfortable in denim. Available in relaxed, regular and slim fits and multiple washes. The non-denim pant is crafted from a performance synthetic fabric with moisture wicking that’s ideal for an active lifestyle.

  • Lee X Soft Denim: Designed for Comfort

    Made with a blend of premium cotton, stretch fibers and Tencel™, the Men’s Lee X Soft Jean offers exceptional softness yet remains durable. Available in regular and slim fits, this jean will get softer with every wash yet is built to last.

  • Lee X Lite Non-Denim: Designed to Breathe

    This synthetic pant is designed to keep you cool no matter how your day heats up. Made from lightweight, breathable stretch fabric, Lee X Lite provides maximum comfort. Available in a regular fit with a tapered leg. Available Spring 2025.
  • Lee X Shirts

    These tailored shirts are made to pair with the Lee X bottoms. Each features a cotton blend fabric with water-repellent technology and stretch, perfect for both work and play.

Find Lee X Move and Lee X Soft now on Lee.com and Amazon.com; Lee X Lite will be available in spring. Pricing starts at $40 for tops and $50 for bottoms. For more information, please visit: https://www.lee.com/leex

About Lee®

Lee®, a Kontoor Brands (NYSE: KTB) brand, has been a pioneer in purposefully designed denim and casual apparel for more than 130 years. As an iconic American brand, Lee’s heritage is filled with fashion firsts marked by innovative fits, era-defining silhouettes, and legendary details in styles for men, women, and boys. Lee’s youthful energy, unrelenting optimism and fearless confidence have created generations of brand loyalists across the globe. For more information, visit www.lee.com.

Tencel™ is the brand name of lyocell fabric produced by Lenzig. TruTemp365 is a U.S. Registered trademark of Unifi, Inc.

[email protected]

KEYWORDS: North Carolina United States North America

INDUSTRY KEYWORDS: Fashion Online Retail Retail Consumer Manufacturing Men Textiles

MEDIA:

Logo
Logo
Photo
Photo
The new Lee X platform incorporates the latest fabric and design innovations into performance-based modern styles. Photo Credit: ©Lee
Posted on

Cognizant Leads Enterprises into Next Generation of AI Adoption with Neuro® AI Multi-Agent Accelerator and Multi-Agent Services Suite

PR Newswire

New development framework and services fast track multi-agent adoption by enabling interoperability and scalability to transform business processes


TEANECK, N.J.
, Jan. 16, 2025 /PRNewswire/ — Cognizant (NASDAQ:CTSH) has announced its Neuro® AI Multi-Agent Accelerator and Multi-Agent Service Suite. These new offerings accelerate the development and adoption of AI agents, helping empower businesses to transform their business processes using AI agents for adaptive operations, real-time decision-making, and personalized customer experiences – to support all facets of business, from IT and finance to sales and marketing.

Businesses are dealing with market volatility, operational complexity, and competition from AI-native companies. Traditional workflows and fixed automation no longer meet most customer expectations because of escalating costs and demand for real-time adaptability, and agentic systems are helping bridge the gap.

Designed to expedite agentic AI adoption, Neuro® AI Multi-Agent Accelerator is a no-code development framework which includes a collection of pre-built, reference agent networks that enable businesses to rapidly prototype, customize and scale multi-agent systems. Pre-built multi-agent network templates provide a starting point for clients to address a range of enterprise functions such as Sales and Marketing, Finance, and Investor Relations, as well as industry-specific processes including Supply Chain Management, Customer Service, and Insurance Underwriting. Additional agent networks can be rapidly created using natural language descriptions to fit different scenarios and client use cases and expanded to include third-party agents.

Neuro AI® Multi-Agent Accelerator is part of the Multi-Agent Services Suite, a broader suite of services that are designed to accelerate the transformation of business processes. This suite of services helps businesses seamlessly create and deploy multi-agent systems using a standardized, proven approach. These services help organizations redesign their business processes, develop and deploy intelligent agent systems, and efficiently manage them in production. In addition, enhanced security and compliance mean that clients can meet regulatory and legal requirements more easily.

“We are entering a pivotal era for human-plus-machine collaboration. Enterprises persisting with stand-alone agents to duplicate human work will struggle to achieve value,” said Phil Fersht, CEO and Chief Analyst, HFS Research. “Rather, they must deploy genuine organizational intelligence where agents and their human counterparts bring contextual intelligence to enhance workflows, datasets, and processes to deliver outcomes.”

“AI agents are transforming enterprise operations through task automation and reducing manual effort, enabling employees to focus on strategic activities,” said Babak Hodjat, CTO of AI at Cognizant. “However, without collaboration among specialized agents, software systems will remain disconnected from larger business goals. Neuro® AI Multi-Agent Accelerator and the Multi-Agent Service Suite allow clients to quickly build and deploy agents into the fabric of their organization, so that they work together across entire businesses to assist humans in lots of roles, from finance and IT to marketing and sales.”

“The rise of autonomous agent networks in enterprise workflows underscores the urgent need for a structured framework enabling seamless interaction and coordination among agents,” said Vishal Gupta, Partner, Data and AI, Everest Group. “Cognizant tackles this challenge head-on, with a multi-agent development framework that delivers a solution laser-focused on scalability and interoperability— pivotal concerns for enterprises seeking to integrate agents into their infrastructure effectively.” 

Multi-agent systems go beyond single agents by enabling decentralized decision-making, where agents act independently yet collaboratively to solve complex, interdependent problems. They are designed to provide scalability across functions and geographies, allow expansion without overhauling systems, and offer resilience through redundancy, ensuring continuity even if individual agents fail.

Neuro AI® Multi-Agent Accelerator offers:

  • Accelerated Agentification Process: pre-built multi-agent networks offer customizable building blocks that incorporate industry and functional best practices. Instead of designing everything from scratch, organizations can start with proven AI agent networks, reducing implementation time and technical risks. Customizing these networks allows for differentiation and adaptation to unique client needs while maintaining the speed and reliability advantage of the pre-built network
  • Fast and Simple Customization: new multi-agent networks can be rapidly created using natural language descriptions to fit different scenarios and client use cases
  • Scalable, Distributed Operation with Smart Task Routing:

    • integrate newly developed multi-agent networks with pre-existing and other third-party agentic systems using simple APIs.
    • encapsulation of agent responsibilities allows for extensibility and automatic routing of tasks to the right AI agents
    • ambiguity resolution over the network of agents, allows new agents to be added more easily while minimizing errors and improving response times
    • manage large workloads by distributing tasks across multiple servers
  • Flexibility in AI and Cloud Provider Choice: switch between all open-source and most commercial LLMs as well as private/public cloud providers without system rebuilds, avoiding vendor lock-in and optimizing cost.

Cognizant is already helping clients transform their businesses with multi-agent solutions. For instance, an insurance company improved investor relations and call analysis by implementing a multi-agent system designed by Cognizant, while a healthcare company created a Contract Negotiator agent network that sped up medical appeal processing times.

Cognizant’s Neuro AI® Multi-Agent Accelerator and Multi Agent Services Suite are available today. For more information about Cognizant’s new Neuro AI® Multi-Agent Accelerator and Multi-Agents Services Suite, click here.

About Cognizant

Cognizant (Nasdaq: CTSH) engineers modern businesses. We help our clients modernize technology, reimagine processes and transform experiences so they can stay ahead in our fast-changing world. Together, we’re improving everyday life. See how at www.cognizant.com or @cognizant

For more information, contact:

Corporate 
Gabby Gugliocciello
[email protected]


India
 
Rashmi Vasisht 
[email protected] 

Americas / EMEA / APJ 
Christina Schneider
[email protected] 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cognizant-leads-enterprises-into-next-generation-of-ai-adoption-with-neuro-ai-multi-agent-accelerator-and-multi-agent-services-suite-302352617.html

SOURCE Cognizant